Skip to main content

Table 1 Recipient/donor baseline and clinical characteristics of ABO-compatible and ABO-identical LTx

From: ABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation

Variables

ABO-compatible (n = 53)

ABO-identical (n = 262)

p-value

Recipient data

   

Recipients major indication

  

0.240

 COPD

10 (18.9%)

64 (24.4%)

 

 AAT1

9 (17.0%)

49 (18.7%)

 

 PH

7 (13.2%)

29 (11.1%)

 

 CF

15 (28.3%)

43 (16.4%)

 

 PF

9 (17.0%)

35 (13.4%)

 

 Others

2 (3.8%)

25 (9.5%)

 

 Graft failure (Re-LTx)

1 (1.8%)

17 (6.5%)

 

 CMV serology (pos)

39 (73.6%)

205 (78.2%)

0. 573

 EBV serology (pos)

37 (69.8%)

184 (70.2%)

0. 920

 Toxoplasma serology (pos)

14 (26.4%)

62 (23.7%)

0. 680

 CMV-mismatch

8 (15.1%)

41 (15.6%)

0. 911

 EBV-mismatch

5 (9.4%)

17 (6.5%)

0. 448

 Toxoplasma mismatch

6 (11.3%)

31 (11.8%)

0. 916

 Weight (kg)

64. 3 ± 19. 9

59. 8 ± 12. 5

0. 032

 Recipient/Donor weight ratio

0. 9 (0. 4–3. 1)

0. 8 (0. 4–1. 6)

0. 034

 Height (cm)

169. 1 ± 9. 1

168. 6 ± 10. 4

0. 703

 Recipient/Donor height ratio

1. 0 (0. 9–2. 4)

0. 9 (0. 8–1. 1)

0. 692

 BMI

22. 2 ± 4. 2

20. 9 ± 3. 7

0. 045

 Male

28 (52.8%)

124 (47.3%)

0. 465

 Gender mismatch

16 (30.2%)

90 (34.4%)

0. 523

 Age (years)

45. 5 (12. 2–70. 6)

52. 9 (12. 4–72. 0)

0. 159

 Recipient/Donor age ratio

0. 97 (0. 30–3. 92)

1. 03 (0. 27–3. 99)

0. 102

 Waiting list (days)

49.0 (2. 0–641. 0)

89. 0 (1. 0–1717. 0)

0. 048

Lab values

   

 FVC (liters)

2. 0 (0. 7–5. 2)

2. 1 (0. 3–5. 3)

0. 233

 FEV1 (liters)

0. 9 (0. 2–2. 6)

0. 8 (0. 2–3. 4)

0. 735

 6MWT (%)

39. 4 ± 20. 3

38. 6 ± 19. 4

0. 813

 P-ALT (μkat/L)

0. 4 (0. 1–9. 7)

0. 4 (0. 1–1. 6)

0. 128

 P-AST (μkat/L)

0.5 (0. 2–10. 0)

0. 4 (0. 2–2. 3)

0. 340

 P-creatinine (μmol/L)

66 (22–234)

62 (26–217)

0. 255

 Pulm. pressure > 25mmhg

20 (37.8%)

70 (26.7%)

0. 110

Tx-type

  

0. 121

 SLTx

14 (26.5%)

86 (32.8%)

 

 DLTx

36 (67.9%)

157 (59.9%)

 

 HLTx

2 (3.8%)

2 (0.8%)

 

 Re-LTx

1 (1.8%)

17 (6.5%)

 

 SLTx

1 (100%)

9 (52.9%)

 

 DLTx

0 (0%)

8 (47.1%)

 

 ATG

35 (66.0%)

172 (65.6%)

0. 908

Pre-op Life support

   

 Mechanical ventilation

2 (3.8%)

12 (4.6%)

0. 795

 ECMO

3 (5.7%)

9 (3.4%)

0. 673

Donor data

   

 CMV serology (pos)

32 (60.4%)

172 (65.6%)

0. 547

 EBV serology (pos)

22 (41.5%)

139 (53.1%)

0. 119

 Toxoplasma serology (pos)

8 (15.1%)

48 (18.3%)

0. 568

 Weight (kg)

70 (19–180)

71 (40–105)

0. 901

 Height (cm)

170 (70–198)

170 (150–190)

0. 886

 BMI

23. 9 (6. 2–34. 6)

23. 9 (14. 7–35. 9)

0. 999

 Male

27 (50.9%)

119 (45.4%)

0. 506

 Age (years)

50. 5 (12. 2–71. 4)

47. 0 (7. 8–75. 4)

0. 463

  1. Data are mean (SD), number (%), or median (range). The numbers are based on patients with data available
  2. Entries are bold due to being under 0.05 which are significant results
  3. COPD chronic obstructive pulmonary disease, AAT1 Alpha 1-antitrypsin deficiency, PH pulmonary hypertension, CF cystic fibrosis; PF, pulmonary fibrosis, CMV cytomegalovirus; EBV Epstein-barr virus; BMI, body-mass index, FVC forced volume vital capacity, FEV1 forced volume expiratory capacity 1 s, 6MWT 6-min walking test, AST aspartate transaminase; ALT alanine transaminase, SLTx, single-lung transplantation, DLTx double-lung transplantation, HLTx heart-lung transplantation, Re-LTx re-lungtransplantation, ATG anti-thymocyte globulin, ECMO extracorporeal membrane oxygenation